Caseware UK (AP4) 2024.0.164 2024.0.164 2025-06-302025-06-30true2024-07-01false2No description of principal activity2trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 10833645 2024-07-01 2025-06-30 10833645 2023-07-01 2024-06-30 10833645 2025-06-30 10833645 2024-06-30 10833645 2023-07-01 10833645 c:Director1 2024-07-01 2025-06-30 10833645 d:PlantMachinery 2025-06-30 10833645 d:PlantMachinery 2024-06-30 10833645 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 10833645 d:OfficeEquipment 2024-07-01 2025-06-30 10833645 d:CurrentFinancialInstruments 2025-06-30 10833645 d:CurrentFinancialInstruments 2024-06-30 10833645 d:CurrentFinancialInstruments d:WithinOneYear 2025-06-30 10833645 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 10833645 d:ShareCapital 2025-06-30 10833645 d:ShareCapital 2024-06-30 10833645 d:RevaluationReserve 2024-07-01 2025-06-30 10833645 d:RevaluationReserve 2025-06-30 10833645 d:RevaluationReserve 2024-06-30 10833645 d:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30 10833645 d:RetainedEarningsAccumulatedLosses 2025-06-30 10833645 d:RetainedEarningsAccumulatedLosses 2024-06-30 10833645 d:AcceleratedTaxDepreciationDeferredTax 2025-06-30 10833645 d:AcceleratedTaxDepreciationDeferredTax 2024-06-30 10833645 d:TaxLossesCarry-forwardsDeferredTax 2025-06-30 10833645 d:TaxLossesCarry-forwardsDeferredTax 2024-06-30 10833645 c:OrdinaryShareClass1 2024-07-01 2025-06-30 10833645 c:OrdinaryShareClass1 2025-06-30 10833645 c:OrdinaryShareClass1 2024-06-30 10833645 c:OrdinaryShareClass2 2024-07-01 2025-06-30 10833645 c:OrdinaryShareClass2 2025-06-30 10833645 c:OrdinaryShareClass2 2024-06-30 10833645 c:FRS102 2024-07-01 2025-06-30 10833645 c:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 10833645 c:FullAccounts 2024-07-01 2025-06-30 10833645 c:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 10833645 d:WithinOneYear 2025-06-30 10833645 d:WithinOneYear 2024-06-30 10833645 d:BetweenOneFiveYears 2025-06-30 10833645 d:BetweenOneFiveYears 2024-06-30 10833645 2 2024-07-01 2025-06-30 10833645 5 2024-07-01 2025-06-30 10833645 6 2024-07-01 2025-06-30 10833645 e:PoundSterling 2024-07-01 2025-06-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 10833645









J P R MEDICAL LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

 
J P R MEDICAL LIMITED
REGISTERED NUMBER: 10833645

BALANCE SHEET
AS AT 30 JUNE 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 3 
13,253
16,566

Investments
 4 
57,864
54,205

  
71,117
70,771

Current assets
  

Debtors: amounts falling due within one year
 5 
34,000
31,500

Bank and cash balances
  
423,005
339,357

  
457,005
370,857

Creditors: amounts falling due within one year
 6 
(58,812)
(38,811)

Net current assets
  
 
 
398,193
 
 
332,046

Total assets less current liabilities
  
469,310
402,817

Provisions for liabilities
  

Deferred tax
 7 
(5,279)
(5,193)

Net assets
  
464,031
397,624


Capital and reserves
  

Called up share capital 
 8 
100
100

Revaluation reserve
 9 
5,898
3,154

Profit and loss account
 9 
458,033
394,370

  
464,031
397,624


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

Page 1

 
J P R MEDICAL LIMITED
REGISTERED NUMBER: 10833645
    
BALANCE SHEET (CONTINUED)
AS AT 30 JUNE 2025

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 13 August 2026.




Dr P P Gopinath
Director

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

1.


General information

J P R Medical Limited ("the Company") is a private company, limited by shares and is incorporated in England and Wales. The address of the registered office is Leytonstone House, 3 Hanbury Drive, Leytonstone, London, E11 1GA.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 3

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.Accounting policies (continued)

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.Accounting policies (continued)


2.7
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following annual basis:

Office and computer equipment
-
20%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

Revaluation of tangible fixed assets

Individual freehold and leasehold properties are carried at current year value at fair value at the date of the revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. Revaluations are undertaken with sufficient regularity to ensure the carrying amount does not differ materially from that which would be determined using fair value at the balance sheet date.

Fair values are determined from market based evidence normally undertaken by professionally qualified valuers.

Revaluation gains and losses are recognised in other comprehensive income unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the excess losses are recognised in profit or loss.

 
2.9

Valuation of investments

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment.

 
2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

 
2.12

Creditors

Short-term creditors are measured at the transaction price.

Page 5

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.Accounting policies (continued)

 
2.13

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.14

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Page 6

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

2.Accounting policies (continued)

 
2.15

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Tangible fixed assets


Plant and machinery

£



Cost


At 1 July 2024
34,551



At 30 June 2025

34,551



Depreciation


At 1 July 2024
17,985


Charge for the year on owned assets
3,313



At 30 June 2025

21,298



Net book value



At 30 June 2025
13,253



At 30 June 2024
16,566


4.


Fixed asset investments





Listed investments

£



Cost or valuation


At 1 July 2024
54,205


Revaluations
3,659



At 30 June 2025
57,864




Page 7

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

5.


Debtors

2025
2024
£
£

Accrued income
34,000
31,500



6.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
-
3,796

Corporation tax
47,657
22,989

Other taxation and social security
698
1,493

Other creditors
2,095
7,533

Accruals
8,362
3,000

58,812
38,811



7.


Deferred taxation




2025
2024


£

£



At beginning of year
5,193
4,232


Charged to profit or loss
915
1,051


Utilised in year
(829)
(90)



At end of year
5,279
5,193

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
3,313
4,142

Revaluation of fixed asset investments
1,966
1,051

5,279
5,193

Page 8

 
J P R MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025

8.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



50 (2024 - 50) Ordinary A shares of £1.00 each
50
50
50 (2024 - 50) Ordinary B shares of £1.00 each
50
50

100

100



9.


Reserves

Revaluation reserve

The revaluation reserve comprises of accumulated revaluation gains and losses, net of any deferred tax and other adjustments.

Profit and loss account

The profit and loss account reserve represents cumulative distributable profits and losses net of dividends and other adjustments.


10.


Commitments under operating leases

At 30 June 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
6,701
6,701

Later than 1 year and not later than 5 years
5,026
11,727

11,727
18,428


11.


Related party transactions

At the period end, the Company owed the directors £2,095 (2024 - £7,533).

 
Page 9